Effect of exchange rate changes on cash
and cash equivalents 15,990 2,128
---------- ----------
Net change in cash and cash equivalents (85,617) (227,018)
Cash and cash equivalents at beginning
of period 322,045 520,610
---------- ----------
Cash and cash equivalents at end of period $236,428 $293,592
========== ==========
Supplemental Cash Flow Information:
Cash paid during the period-
Interest $57,663 $23,434
Income taxes, net $57,623 $21,224
Hospira, Inc.
Net Sales by Product Line
(Unaudited)
(dollars in thousands)
Three Months Ended Nine Months Ended
September 30, September 30,
-------------------------- -----------------------------
2007 2006 % Change 2007 2006 % Change
-------- ------- -------- ---------- --------- --------
U.S. --
Specialty
Injectable
Pharmaceuticals $208,363 $198,362 5.0 % $619,761 $590,915 4.9 %
Medication
Delivery
Systems 216,245 199,029 8.6 % 660,049 626,498 5.4 %
Injectable
Pharmaceutical
Contract
Manufacturing 33,518 38,090 (12.0)% 111,632 139,879 (20.2)%
Sales to Abbott
Laboratories 18,604 25,038 (25.7)% 55,791 70,860 (21.3)%
Mayne Pharma
'/>"/>
| SOURCE Hospira, Inc. Copyright©2007 PR Newswire. All rights reserved |